UK-based Antiverse Ltd is to extend a collaboration with GlobalBio Inc, a US antibody engineering company, to identify new checkpoint inhibitors for cancer. This follows the successful generation of two candidate anti-PD-1 antibodies that are now entering preclinical development. Financial terms of the agreement were not disclosed.
The collaboration combines Antiverse’s discovery technology, which is based on artificial intelligence, with GlobalBio’s semisynthetic libraries for the discovery and optimisation of antibody-based therapeutics.